The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
What is the role of human beta-defensin-2 in modulation of the microbiome and aGvHD?
Featured:
Robert ZeiserDuring the EHA 2022 Congress, the GvHD Hub was pleased to speak to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE. We asked, What is the role of human beta-defensin-2 (HBD-2) in modulation of the microbiome and acute GvHD (aGvHD)?
What is the role of human beta-defensin-2 in modulation of the microbiome and aGvHD?
Zeiser begins by discussing the high frequency of patients who develop aGvHD despite receiving prophylaxis. Zeiser also talks about the antimicrobial, immunosuppressive, and immunomodulatory functions of HBD-2, and how it can affect GvHD development and severity.